title: Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis.
abstract: OBJECTIVE
  To better understand the molecular mechanisms that underlay the development and progression of nonseminomatous germ cell tumor of testis (NSGCTT) as well as malignant transformation of teratoma and primitive neuroectodermal tumor (PNET).
  
  
  METHODS
  We studied the gene expression profiles of 17 retroperitoneal NSGCTTs (10 yolk sac tumors, 3 embryonal carcinomas, 4 teratomas) and 2 PNETs obtained from patients with two clinical outcomes. Tissue samples were obtained from the Indiana University. One group of NSGCTT and PNET patients developed metastases within 2 years (early-relapse) of initial successful treatment, and the other group developed metastases after 2 years (late-relapse). Gene expression in these groups of patients was quantified using cDNA microarrays and real-time relative quantitative PCR.
  
  
  RESULTS
  We demonstrate that the gene expression profiles of these tumors correlate with histological type. In addition, we identify type-specific genes that may serve as novel diagnostic markers. We also identify a gene set that can distinguish between early-relapse and late-relapse yolk sac tumors. The expression differences of these genes may underlie the differences in clinical outcome and drug response of these tumors.
  
  
  CONCLUSIONS
  This is the first study that used gene expression profiling to examine the molecular characteristics of the NSGCTTs and drug response in early- and late-relapse tumors. These results suggest that two molecularly distinct forms of NSGCTTs exist and that the integration of expression profile data with clinical parameters could enhance the diagnosis and prognosis of NSGCTTs. More importantly, the identified genes provide insight into the molecular mechanisms of aggressive NSGCTTs and suggest intervention strategies.
authors.affiliation: Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Sugimura
authors.forename: Richard S
authors.initials: RS
authors.lastname: Foster
authors.forename: Oscar W
authors.initials: OW
authors.lastname: Cummings
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Kort
authors.forename: Masayuki
authors.initials: M
authors.lastname: Takahashi
authors.forename: Todd T
authors.initials: TT
authors.lastname: Lavery
authors.forename: Kyle A
authors.initials: KA
authors.lastname: Furge
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Einhorn
authors.forename: Bin Tean
authors.initials: BT
authors.lastname: Teh
mesh_terms: D002471:Cell Transformation, Neoplastic; D002869:Chromosome Aberrations; D018076:DNA, Complementary / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009373:Neoplasms, Germ Cell and Embryonal / Q000235:genetics* / Q000378:metabolism*; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013724:Teratoma / Q000378:metabolism; D013736:Testicular Neoplasms / Q000235:genetics* / Q000378:metabolism*; D013997:Time Factors
chemical_list: D018076:DNA, Complementary